Launched at the 7th Tokyo International Conference on African Development (TICAD7)
Dubai: Alwaleed Philanthropies, chaired by HRH Prince Alwaleed Bin Talal Bin Abdulaziz AlSaud, the global philanthropic foundation, has made a fresh commitment to preventing the spread of disease by investing a further US $5 million in its partnership with Gavi, the Vaccine Alliance.
The commitment will provide extra funding between 2020 and 2024 to support organisations known by Gavi as ‘pacesetters’ that are developing new innovations to improve vaccine access and delivery, particularly in urban areas. The foundation will make the investment through Gavi’s INFUSE initiative (Innovation for Uptake, Scale and Equity in Immunisation), which identifies these ‘pacesetters’, provides funding and support for them, and connects them to authorities in countries that need vaccination support.
The grant is part of a range of efforts by Alwaleed Philanthropies to improve routine immunisation and contributes to Gavi’s mission to ensure that every child is immunised with basic life-saving vaccines no matter where they live and builds on the original US $1 million investment made in 2015 to support vaccines in Timor Leste, Kiribati, Armenia, Azerbaijan, Moldova, Guyana for the 2016-2020 programme.
HRH Princess Lamia Bint Majid Al Saud, General Secretary of Alwaleed Philanthropies, announced the partnership at the 7th Tokyo International Conference on African Development (TICAD7), hosted by the Japanese government in Yokohama on 30th August.
She said: “Alwaleed Philanthropies places huge importance on its partnership with the Gavi, the Vaccine Alliance – and specifically their INFUSE Initiative – to boost immunisation in the world’s poorest countries. With the majority of the world’s population increasingly living in urban areas, and with more than 19.4 million children still under immunised, we recognise that there has rarely been a more pressing need to support innovation in immunisation.”
Every year INFUSE supports research, entrepreneurship and innovation in areas that help governments, healthcare organisations and other partners reach more children with life-saving vaccines. This year the investment from Alwaleed Philanthropies will support innovations uniquely positioned to address immunisation challenges in urban settings.
By 2050 nearly 70% of the world’s population will live in urban settings. The rapid growth will add nearly 2.5 billion people to urban areas, with 90% of the expansion occurring in Asia and Africa. These large, highly populated urban settings with mobile, transient and under-immunised populations lend themselves to an increased risk of disease transmission and outbreaks.
“Alwaleed Philanthropies has been a steadfast supporter of our mission to ensure no child goes without life-saving vaccines,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “This new funding to INFUSE will help accelerate the introduction of innovations and technology that modernize vaccine delivery systems and ensure vaccines protect all children against deadly diseases. On behalf of Gavi, I’d like to offer my sincere thanks to Alwaleed Philanthropies and HRH Princess Lamia bint Majid Al-Saud for their support.”
About Alwaleed Philanthropies
Alwaleed Philanthropies supports and initiates projects in 189 countries, regardless of the gender, race or religion. We collaborate with a range of philanthropic, government and educational organizations to combat poverty, empower women and youth, develop communities, provide disaster relief and create cultural understanding through education. Together with partners around the world, we build bridges for a more compassionate, tolerant and accepting world.
About Gavi
Gavi, the Vaccine Alliance is a public-private partnership committed to saving children's lives and protecting people's health by increasing equitable use of vaccines in lower-income countries. The Vaccine Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill & Melinda Gates Foundation and other private sector partners. Gavi uses innovative finance mechanisms to secure sustainable funding and adequate supply of quality vaccines. Since 2000, Gavi has contributed to the immunisation of more than 760 million children and the prevention of over 13 million future deaths. Learn more at www.gavi.org and connect with us on Facebook and Twitter.
Gavi, the Vaccine Alliance is supported by donor governments (Australia, Brazil, Canada, Denmark, France, Germany, Iceland, India, Ireland, Italy, Japan, the Kingdom of Saudi Arabia, Luxembourg, the Netherlands, Norway, the People’s Republic of China, Principality of Monaco, Republic of Korea, Russia, South Africa, Spain, the State of Qatar, the Sultanate of Oman, Sweden, Switzerland, United Kingdom, and United States), the European Commission, Alwaleed Philanthropies, the OPEC Fund for International Development (OFID), the Bill & Melinda Gates Foundation, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, as well as private and corporate partners (Absolute Return for Kids, Anglo American plc., The Audacious Alliance, The Children’s Investment Fund Foundation, China Merchants Group, Comic Relief, Deutsche Post DHL, the ELMA Vaccines and Immunization Foundation, Girl Effect, The International Federation of Pharmaceutical Wholesalers (IFPW), the Gulf Youth Alliance, JP Morgan, Kuwait Fund for Arab Economic Development, “la Caixa” Foundation, LDS Charities, Lions Clubs International Foundation, Mastercard, Majid Al Futtaim, Orange, Philips, Reckitt Benckiser, Unilever, UPS and Vodafone).
For media contacts:
Ronak Thakkar
FleishmanHillard
+971 54 586 9828
ronak.thakkar@fleishman.com
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
